Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	73827
Country	United States

Received	2021-12-05 00:05
Peer-Review Started	2021-12-05 00:07
To Make the First Decision
Return for Revision	2021-12-27 04:17
Revised	2021-12-29 19:39
Second Decision	2022-05-11 03:02
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2022-05-13 16:09
Articles in Press	2022-05-13 16:09
Publication Fee Transferred
Edit the Manuscript by Language Editor	2022-05-09 23:51
Typeset the Manuscript	2022-05-31 21:45
Publish the Manuscript Online	2022-06-10 02:05

ISSN	1948-5204 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Letter to the Editor
Article Title	Hepatocellular carcinoma and immunotherapy: Beyond immune checkpoint inhibitors
Manuscript Source	Invited Manuscript
All Author List	Hassan Mohammed Abushukair and Anwaar Saeed
ORCID	Author(s) ORCID Number Hassan Mohammed Abushukair http://orcid.org/0000-0002-0068-5201 Anwaar Saeed http://orcid.org/0000-0001-8024-9401
Funding Agency and Grant Number
Corresponding Author	Anwaar Saeed, MD, N/A, N/A, Division of Medical Oncology, Department of Medicine, The University of Kansas Cancer Center, 2330 Shawnee Mission Pkwy, Kansas City, KS 66205, United States. asaeed@kumc.edu
Key Words	Hepatocellular carcinoma; Immunotherapy; Biomarkers; Cancer vaccines; Adoptive cellular therapy
Core Tip	Immunotherapy has changed the treatment landscape for solid cancers. In advanced hepatocellular carcinoma (HCC), immune checkpoint inhibitors have become the standard of care due to their efficacy and safety outcomes. However, primary and acquired resistance is a major issue in the treatment paradigm, and more research is still needed to understand and identify potential predictors of the response in HCC. Other immunotherapy modalities, such as vaccine therapy and adoptive cellular therapy, could play a prominent role in certain HCC subcohorts and are currently being investigated in clinical trial settings.
Publish Date	2022-06-10 02:05
Citation	Abushukair HM, Saeed A. Hepatocellular carcinoma and immunotherapy: Beyond immune checkpoint inhibitors. World J Gastrointest Oncol 2022; 14(6): 1210-1212
URL	https://www.wjgnet.com/1948-5204/full/v14/i6/1210.htm
DOI	https://dx.doi.org/10.4251/wjgo.v14.i6.1210

Full Article (PDF)	WJGO-14-1210.pdf
Full Article (Word)	WJGO-14-1210.docx
Manuscript File	73827_Auto_Edited_LM.docx
Answering Reviewers	73827-Answering reviewers.pdf
Audio Core Tip	73827-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	73827-Conflict-of-interest statement.pdf
Copyright License Agreement	73827-Copyright license agreement.pdf
Peer-review Report	73827-Peer-review(s).pdf
Scientific Misconduct Check	73827-Bing-Fan JR-2.png
Scientific Editor Work List	73827-Scientific editor work list.pdf
CrossCheck Report	73827-CrossCheck report.pdf
CrossCheck Report	73827-CrossCheck.png